Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder
Trial details
- Registry ID
- NCT04276883
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as Dexmedetomidine
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Dexmedetomidine in the Treatment of Agitation Associated With Bipolar DisorderNCT04276883 | BioXcel Therapeutics Inc | Phase 3 | Completed | 2020-05-21Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |